Aesthetic Medicine News
Portland, OR — June 23, 2026 | By Cosmetiq Medicine
Health Canada has approved Boey® (trenibotulinumtoxinE), a fast-acting neurotoxin that produces visible results in as little as eight hours and fades within two to three weeks — a fundamentally different option from the months-long results patients expect from traditional Botox-style treatments.
What was approved
On June 23, 2026, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced that Health Canada has approved Boey® for the temporary improvement of moderate to severe glabellar lines — the vertical lines between the eyebrows commonly called frown lines — in adult patients. Canada is the first country in the world to approve this treatment.
Boey is built on botulinum neurotoxin serotype E, distinct from the serotype A used in BOTOX® Cosmetic and most other neurotoxins on the market today. That difference is what drives its signature trait: a rapid onset of action, with visible results reported as early as eight hours after injection, and a notably short duration, with effects fading within roughly 14 to 21 days.
By comparison, traditional neurotoxins like BOTOX® Cosmetic typically take three to seven days to take effect and last three to four months. Boey isn’t positioned to replace that — it’s a new category of treatment built for a different patient need entirely.
Why Allergan built a short-duration neurotoxin
The approval is backed by two Phase 3 clinical trials (M21-500 and M21-508), which enrolled a combined 947 patients with moderate to severe glabellar lines. At Day 7, 60.0% and 65.7% of patients in the two trials achieved the study’s efficacy benchmark — “none or mild” line severity with at least a 2-grade improvement from baseline — a statistically significant result (p<0.0001) versus placebo.
The most common treatment-related side effects were headache (3.4%), injection site pain (1.7%), and injection site redness (0.6%) — each reported at rates lower than or comparable to placebo in the trials.
Allergan’s own research points to the gap Boey is meant to fill. According to a company survey of nearly 12,300 adults across multiple countries, 80% of respondents said they’re open to learning about new aesthetic treatments, and 79% said they wish they could “preview” the outcome of a treatment before committing to it. A short-duration neurotoxin gives hesitant patients a lower-stakes way to try injectables without a three- or four-month commitment.
“As the world’s first approval of a botulinum neurotoxin based on serotype E in aesthetics, Boey represents a meaningful advancement in aesthetic medicine — a fast-acting neurotoxin with a differentiated profile that expands the treatment options for clinicians and patients.”
— Roopal Thakkar, M.D., Chief Scientific Officer, AbbVie
When patients might actually be able to get it
This approval is specific to Canada. Allergan Aesthetics says it plans to begin training healthcare professionals on Boey and is preparing for a commercial launch there “in the upcoming months,” while trenibotulinumtoxinE is under regulatory review in multiple other countries — including, expected eventually, the United States. There’s no confirmed U.S. approval or timeline yet, and the FDA process is separate from Health Canada’s.
For patients in the Portland and Vancouver, WA area following this story: nothing changes immediately for treatment options here. But it’s a useful preview of where injectable aesthetics is heading — toward more choice in how long results last, not just how strong they are. If you’re currently weighing Botox or Dysport against other options, it’s worth raising with your provider during a consultation — not because Boey is available yet, but because “how long do you actually want this to last” is a question worth asking regardless of which neurotoxin ends up being right for you.
The bottom line
Boey’s Health Canada approval marks the global debut of an entirely new neurotoxin category — not a longer-lasting or stronger alternative to BOTOX® Cosmetic, but a deliberately short-lived one, aimed at people who want to test the waters of facial injectables without a multi-month commitment. Whether and when it reaches U.S. patients is still an open question, but the approval itself signals that the aesthetic medicine industry is starting to treat “duration” as its own design choice — not just a side effect of dose.
Frequently Asked Questions
What is Boey, and how is it different from Botox?
Boey (trenibotulinumtoxinE) is a botulinum neurotoxin built on serotype E, rather than the serotype A used in BOTOX® Cosmetic and most other neurotoxins. That difference gives it a much faster onset — visible results in as little as eight hours — and a much shorter duration of roughly 14 to 21 days, compared to three to four months for traditional neurotoxins.
Where has Boey been approved, and is it available in the United States?
Health Canada approved Boey on June 23, 2026, making Canada the first country in the world to do so. It is not yet approved in the United States. TrenibotulinumtoxinE is under regulatory review in multiple other countries, but there is no confirmed U.S. approval or timeline yet.
What does the clinical trial data show?
Two Phase 3 trials enrolling a combined 947 patients with moderate to severe glabellar lines found that 60.0% and 65.7% of patients achieved the study’s efficacy benchmark at Day 7, a statistically significant result versus placebo. The most common side effects were headache, injection site pain, and injection site redness, each reported at rates comparable to or lower than placebo.
Why would someone want a neurotoxin that wears off faster?
According to Allergan’s own survey of nearly 12,300 adults, a large share of people are curious about aesthetic treatments but hesitant to commit to a result that lasts three to four months. A short-duration option lets patients try a neurotoxin with lower stakes, since any result fades within a few weeks rather than requiring a long commitment.
Does this approval change anything for patients right now?
Not immediately. Boey is not yet available outside Canada, and Allergan has not announced U.S. provider training or a launch timeline. For now, it’s a signal of where injectable aesthetics may be heading rather than a treatment patients elsewhere can currently access.
Sources: AbbVie / Allergan Aesthetics official press release via StockTitan, June 23, 2026; additional reporting via Grafa, June 23, 2026.
